Precision BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Precision BioSciences, Inc.
Base editing has reached a new milestone as Beam’s lead candidate gets the green light for clinical trials, and its peer Verve Therapeutics is not far behind, while big pharma dips its toes in the water.
Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Elo Life Systems
- Precision PlantSciences